Clinical Pediatric Endocrinology最新文献_第5页

Lithium as an alternative option in thionamide-resistant Graves' disease. 锂作为抗硫胺格雷夫斯病的替代选择。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2022-0070

Ying Ki Chung, Lap Ming Wong

引用次数: 1

Letter to the Editor: International standard growth charts overestimate stunting prevalence in Nabire and Jakarta, Indonesia, compared to the Indonesian national growth chart. 致编辑的信:与印度尼西亚国家增长图表相比，国际标准增长图表高估了印度尼西亚纳比雷和雅加达的发育迟缓发生率。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2023-0018

Callum Lowe

引用次数: 0

Glucokinase maturity-onset diabetes of the young as a mimicker of stress hyperglycemia: a case report. 葡萄糖激酶成熟型糖尿病的年轻人作为模拟应激性高血糖:一个案例报告。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2022-0024

Yoshitaka Nakasato, Shintaro Terashita, Shohei Kusabiraki, Sadashi Horie, Takuya Wada, Motokazu Nakabayashi, Megumi Nakamura, Tohru Yorifuji

{"title":"Glucokinase maturity-onset diabetes of the young as a mimicker of stress hyperglycemia: a case report.","authors":"Yoshitaka Nakasato, Shintaro Terashita, Shohei Kusabiraki, Sadashi Horie, Takuya Wada, Motokazu Nakabayashi, Megumi Nakamura, Tohru Yorifuji","doi":"10.1297/cpe.2022-0024","DOIUrl":"https://doi.org/10.1297/cpe.2022-0024","url":null,"abstract":"Abstract. Febrile seizures are frequently accompanied by stress-induced hyperglycemia. Herein, we report the case of a 1.5-yr-old girl with hyperglycemia during febrile seizures who was subsequently diagnosed with glucokinase (GCK) maturity-onset diabetes of the young (MODY), considering its distinction from stress hyperglycemia. Following the development of febrile seizures owing to adenovirus infection, the patient presented a casual blood glucose level was 185 mg/dL. She had a multigenerational family history of diabetes and a hemoglobin A1c (HbA1c) level of 6.4%. Owing to the persistent glucose intolerance until the age of 5 years, genetic testing was performed, which revealed a heterozygous mutation in GCK, and the patient was diagnosed with GCK-MODY. Precise diagnosis of GCK-MODY individuals is important to avoid administering unnecessary antidiabetic medications. Even during hyperglycemia under stress, multigenerational diabetes and mildly elevated HbA1c levels can suggest GCK-MODY.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/05/cpe-32-072.PMC9887293.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9241564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Ultrasonography-based reference values for the cross-sectional area of the thyroid gland in children and adolescents: The Fukushima Health Management Survey. 基于超声的儿童和青少年甲状腺横截面积参考值:福岛健康管理调查。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2022-0057

Haruka Ejiri, Mahiro Asano, Nana Nakahata, Satoshi Suzuki, Ayako Sato, Natsuki Nagamine, Chisato Takahashi, Yukie Yamaya, Manabu Iwadate, Takashi Matsuzuka, Tetsuya Ohira, Seiji Yasumura, Satoru Suzuki, Fumihiko Furuya, Hiroki Shimura, Shinichi Suzuki, Susumu Yokoya, Hitoshi Ohto, Kenji Kamiya

{"title":"Ultrasonography-based reference values for the cross-sectional area of the thyroid gland in children and adolescents: The Fukushima Health Management Survey.","authors":"Haruka Ejiri, Mahiro Asano, Nana Nakahata, Satoshi Suzuki, Ayako Sato, Natsuki Nagamine, Chisato Takahashi, Yukie Yamaya, Manabu Iwadate, Takashi Matsuzuka, Tetsuya Ohira, Seiji Yasumura, Satoru Suzuki, Fumihiko Furuya, Hiroki Shimura, Shinichi Suzuki, Susumu Yokoya, Hitoshi Ohto, Kenji Kamiya","doi":"10.1297/cpe.2022-0057","DOIUrl":"https://doi.org/10.1297/cpe.2022-0057","url":null,"abstract":"We previously described the thyroid volume, which was calculated by measuring the thyroid width, thickness, and longitudinal length using ultrasonography, in children and adolescents. We have proposed a simplified method for quantitatively assessing the thyroid size, to overcome the inaccuracy and challenges in measuring the longitudinal length of the thyroid. Based on measurements of 317,847 (girls: 156,913, boys: 160,934) children and adolescents, we calculated sex-specific means and standard deviations of thyroid width and thickness, and of the cross-sectional area computed by multiplying them, for every age and 0.1 m2 of body surface area, after ensuring normal distribution with Box-Cox transformation. Multivariate regression analysis revealed that female sex, age, and body surface area were independently associated with areas of each thyroid lobe. Our novel method may be useful in quantitatively assessing the thyroid size, and appropriately diagnosing pathological conditions, such as hypoplasia, atrophy, and enlargement of the thyroid gland, in children and adolescents.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d1/c3/cpe-32-052.PMC9887296.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9241568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safe administration of sotrovimab to a COVID-19 patient with acute phase type 1 diabetes mellitus. sotrovimab对1例COVID-19合并急性1型糖尿病患者的安全应用

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2022-0077

Haruna Tanaka, Masaaki Matsumoto, Sung Won Hong, Akari Mitsuboshi, Masashi Nagai, Go Yoshino, Shogo Otake, Susumu Matsuo, Hiroyuki Yamada, Hiroshi Kurosawa, Masashi Kasai, Kayo Ozaki

{"title":"Safe administration of sotrovimab to a COVID-19 patient with acute phase type 1 diabetes mellitus.","authors":"Haruna Tanaka, Masaaki Matsumoto, Sung Won Hong, Akari Mitsuboshi, Masashi Nagai, Go Yoshino, Shogo Otake, Susumu Matsuo, Hiroyuki Yamada, Hiroshi Kurosawa, Masashi Kasai, Kayo Ozaki","doi":"10.1297/cpe.2022-0077","DOIUrl":"https://doi.org/10.1297/cpe.2022-0077","url":null,"abstract":"Type 1 diabetes mellitus (T1DM) and poor glycemic control are risk factors for severe coronavirus disease 2019 (COVID-19). Sotrovimab can treat mild-to-moderate COVID-19 in patients at a high risk of progression to severe COVID-19. However, its safety and efficacy in T1DM patients remain to be elucidated. We report the case of a 12-yr-old patient who was treated with sotrovimab for COVID-19 immediately after treatment for diabetic ketoacidosis (DKA) due to new-onset T1DM. He presented with nausea and sore throat and was diagnosed with severe DKA and COVID-19. A productive cough and sputum developed after admission. On the 3rd day of admission, the DKA resolved, and sotrovimab was administered to prevent exacerbation of COVID-19. Although the blood glucose levels increased after the administration of sotrobimab, there was no recurrence of DKA. Hyperglycemia may be a sotrovimab-related adverse event in T1DM patients. Nevertheless, the benefits of sotrovimab treatment may far outweigh the potential risks. Thus, sotrovimab was considered safe for patients with T1DM immediately after treatment of severe DKA.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/83/cpe-32-110.PMC10068621.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9626466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowns and unknowns about congenital hypothyroidism: 2022 update. 关于先天性甲状腺功能减退症的已知和未知:2022年更新。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2022-0016

Tomoyo Itonaga, Yukihiro Hasegawa, Shinji Higuchi, Mari Satoh, Hirotake Sawada, Kazuhiro Shimura, Ikuko Takahashi, Noriyuki Takubo, Keisuke Nagasaki

{"title":"Knowns and unknowns about congenital hypothyroidism: 2022 update.","authors":"Tomoyo Itonaga, Yukihiro Hasegawa, Shinji Higuchi, Mari Satoh, Hirotake Sawada, Kazuhiro Shimura, Ikuko Takahashi, Noriyuki Takubo, Keisuke Nagasaki","doi":"10.1297/cpe.2022-0016","DOIUrl":"https://doi.org/10.1297/cpe.2022-0016","url":null,"abstract":"Several excellent guidelines and expert opinions on congenital hypothyroidism (CH) are currently available. Nonetheless, these guidelines do not address several issues related to CH in detail. In this review, the authors chose the following seven clinical issues that they felt were especially deserving of closer scrutiny in the hope that drawing attention to them through discussion would help pediatric endocrinologists and promote further interest in the treatment of CH. 1. How high should the levothyroxine (L-T4) dose be for initial treatment of severe and permanent CH? 2. What is the optimal method for monitoring treatment of severe CH? 3. At what level does maternal iodine intake during pregnancy affect fetal and neonatal thyroid function? 4. Does serum thyroglobulin differ between patients with a dual oxidase 2 (DUOX2) variants and those with excess iodine? 5. Who qualifies for a genetic diagnosis? 6. What is the best index for distinguishing transient and permanent CH? 7. Is there any cancer risk associated with CH? The authors discussed these topics and jointly edited the manuscript to improve the understanding of CH and related issues.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/48/cpe-32-011.PMC9887299.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10747017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Congenital hypothyroidism and thyroid function in a Japanese birth cohort: data from The Japan Environment and Children's Study. 日本出生队列中的先天性甲状腺功能减退症和甲状腺功能：来自日本环境和儿童研究的数据。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 Epub Date: 2023-09-22 DOI: 10.1297/cpe.2022-0068

Limin Yang, Miori Sato, Mayako Saito-Abe, Yumiko Miyaji, Chikako Sato, Minaho Nishizato, Natsuhiko Kumasaka, Hidetoshi Mezawa, Kiwako Yamamoto-Hanada, Yukihiro Ohya

{"title":"Congenital hypothyroidism and thyroid function in a Japanese birth cohort: data from The Japan Environment and Children's Study.","authors":"Limin Yang, Miori Sato, Mayako Saito-Abe, Yumiko Miyaji, Chikako Sato, Minaho Nishizato, Natsuhiko Kumasaka, Hidetoshi Mezawa, Kiwako Yamamoto-Hanada, Yukihiro Ohya","doi":"10.1297/cpe.2022-0068","DOIUrl":"10.1297/cpe.2022-0068","url":null,"abstract":"The most common hormonal and metabolic disease in early childhood is congenital hypothyroidism (CH). This study aimed to describe CH in large-scale birth cohort data and summarize the results of serum thyroid-stimulating hormone (TSH) and free thyroxine (fT4) levels in 2-yr-old children. Data were obtained from the Japan Environment and Children's Study (JECS), and we identified 171 children with CH detected in newborn screenings or medical records (170.5 per 100,000 population). Infants with CH are at higher risk of developing congenital diseases than those without CH. Of 171 children with CH, 20 (11.7%) were diagnosed with congenital heart defects, 33 (19.3%) had chromosomal or other congenital abnormalities, and 23 (13.5%) had Down syndrome. At the age of 2 yr old, the median and 95% reference range values for TSH and fT4 were 2.13 (0.78-5.52) μIU/mL and 1.2 (1.0-1.5) ng/dL, respectively. Moreover, boys had slightly higher TSH and fT4 levels than did girls. Data on the distribution of TSH and fT4 in 2-yr-old children should be useful for decreasing the misclassification of thyroid disorders in the pediatric population. Trial-off treatment and re-evaluation of thyroid function are needed to classify permanent congenital hypothyroidism and transient congenital hypothyroidism after 3 yr of age.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/b8/cpe-32-213.PMC10568570.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pseudo-Bartter syndrome in an infant without obvious underlying conditions: A case report. 无明显基础疾病的婴儿伪巴特综合征1例报告。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2022-0069

Junya Toyoda, Masanori Adachi, Ayako Ochi, Yuki Okada, Aiko Honda, Katsumi Mizuno, Kandai Nozu

{"title":"Pseudo-Bartter syndrome in an infant without obvious underlying conditions: A case report.","authors":"Junya Toyoda, Masanori Adachi, Ayako Ochi, Yuki Okada, Aiko Honda, Katsumi Mizuno, Kandai Nozu","doi":"10.1297/cpe.2022-0069","DOIUrl":"https://doi.org/10.1297/cpe.2022-0069","url":null,"abstract":"Pseudo-Bartter syndrome (PBS) develops owing to renal or extrarenal chloride loss, leading to hypokalemic alkalosis. Whereas most adult cases result from diuretic/laxative abuse, many infantile cases occur secondary to cystic fibrosis. Rarely, infantile PBS is caused by renal salt loss with anomalies of the kidney/urinary tract or genetic disorders, such as Dent disease. Here, we report the case of a 10-mo-old girl with a one-month history of decreased formula intake and 5.6% body weight loss. She showed typical laboratory findings as PBS, including hypokalemia (2.7 mEq/L) and high levels of bicarbonate (32.7 mEq/L) with a plasma renin activity of 399 ng/mL/h. With minimum supplementation of potassium and sodium, an improvement in body mass index, from -1.13 SD to +0.52 SD, with complete resolution of laboratory data was obtained in approximately one month. No causative mutations were identified in candidate genes for Bartter-Gitelman syndrome. Due to profound hypochloruria (< 15 mEq/L), PBS of renal origin was unlikely. In addition, extrarenal chloride loss did not seem to be the case, because the patient never manifested gastrointestinal symptoms. Therefore, we speculate that a temporary decrease in chloride intake, coupled with the putative genetic/epigenetic disadvantage of chloride retention, such as a subtle renal leak, may be responsible for the PBS in our patient.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/02/cpe-32-155.PMC10288294.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9714575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to the Letter to the Editor entitled "Glucokinase maturity-onset diabetes of the young as a mimicker of stress hyperglycemia: a case report" by Amanda Doherty-Kirby, Clin Pediatr Endocrinol 2023;32:72-75. 对Amanda Doherty-Kirby致编辑的题为“年轻人的葡萄糖激酶成熟型糖尿病作为应激性高血糖的模拟物:一个病例报告”的回复，临床儿科内分泌杂志2023;32:72-75。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2023-0001-2

Shintaro Terashita

引用次数: 0

Paracrine and endocrine functions of osteocytes. 骨细胞的旁分泌和内分泌功能。

IF 1.4

Clinical Pediatric Endocrinology Pub Date : 2023-01-01 DOI: 10.1297/cpe.2022-0053

Toshimi Michigami

{"title":"Paracrine and endocrine functions of osteocytes.","authors":"Toshimi Michigami","doi":"10.1297/cpe.2022-0053","DOIUrl":"https://doi.org/10.1297/cpe.2022-0053","url":null,"abstract":"Osteocytes are dendritic-shaped cells embedded in the bone matrix and are terminally differentiated from osteoblasts. Inaccessibility due to their location has hindered the understanding of the molecular functions of osteocytes. However, scientific advances in the past few decades have revealed that osteocytes play critical roles in bone and mineral metabolism through their paracrine and endocrine functions. Sclerostin produced by osteocytes regulates bone formation and resorption by inhibiting Wnt/β-catenin signaling in osteoblast-lineage cells. Receptor activator of nuclear factor κ B ligand (RANKL) derived from osteocytes is essential for osteoclastogenesis and osteoclast activation during postnatal life. Osteocytes also secrete fibroblast growth factor 23 (FGF23), an endocrine FGF that regulates phosphate metabolism mainly by increasing phosphate excretion and decreasing 1, 25-dihydroxyvitamin D production in the kidneys. The regulation of FGF23 production in osteocytes is complex and multifactorial, involving many local and systemic regulators. Antibodies against sclerostin, RANKL, and FGF23 have emerged as new strategies for the treatment of metabolic bone diseases. Improved undrstanding of the paracrine and endocrine functions of osteocytes will provide insight into future therapeutic options.","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/a6/cpe-32-001.PMC9887291.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9241569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2